MPM Oncology Impact Management »

Compass Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Compass Therapeutics (CMPX) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Compass Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Compass Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Compass Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $5.0M 5.0M 1.00
2024-03-31 $3.9M 2.0M 1.98

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Compass Therapeutics

OrbiMed Advisors
Blackstone Group
BlackRock
BlackRock
Rock Springs Capital Management
Henderson Group
MPM Oncology Impact Management
Vanguard Group
Blue Owl Capital Holdings
Geode Capital Management
Cormorant Asset Management
State Street Corporation
Tang Capital Management
Baker Bros. Advisors
Northern Trust

View all funds holding Compass Therapeutics